Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ADRB3 | P13945 | 6/20 | 0.53 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6074194 | 1.00 | PTGS1 (0.57) | PTGS1SLC6A2KMT2ASMN1; SMN2ADRB3 | |
| SCHEMBL11127254 | 0.92 | SMN1; SMN2 (0.61) | KMT2ASMN1; SMN2TSHRLMNAPOLB | |
| SCHEMBL10492789 | 0.87 | PTGS1 (0.65) | PTGS1SLC6A2SMN1; SMN2ADRB3ADRB2 | |
| SCHEMBL10490309 | 0.87 | PTGS1 (0.65) | PTGS1SLC6A2SMN1; SMN2ADRB3ADRB2 | |
| SCHEMBL10077718 | 0.87 | HTT (0.58) | PTGS1SLC6A2KMT2ASMN1; SMN2ADRB3 | |
| SCHEMBL11252520 | 0.84 | PTGS1 (0.58) | PTGS1SLC6A2KMT2ASMN1; SMN2ADRB3 | |
| SCHEMBL10770337 | 0.82 | SMN1; SMN2 (0.53) | KMT2ASMN1; SMN2TSHRLMNAPOLB | |
| SCHEMBL16314627 | 0.82 | SMN1; SMN2 (0.53) | KMT2ASMN1; SMN2TSHRLMNAPOLB | |
| SCHEMBL768290 | 0.82 | KMT2A (0.53) | KMT2ASMN1; SMN2KCNH2TSHRMAPT | |
| SCHEMBL772822 | 0.82 | TSHR (0.65) | KMT2ASMN1; SMN2TSHRLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022716-B2 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH (US) | 2006-04-04 | — | — | US | disclosed |
| US-6821991-B2 | FOR THERAPY OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA (ASSOCIATED WITH OBESITY OR GLUCOSE INTOLERANCE), ATHEROSCLEROSIS, GASTROINTESTINAL DISORDERS, NEUROGENETIC INFLAMMATION, FREQUENT URINATION | WYETH | 2004-11-23 | — | — | US | disclosed |
| US-6743787-B2 | FOR THERAPY OF METABOLIC DISORDERS MEDIATED BY INSULIN RESISTANCE OR HYPERGLYCEMIA IN A MAMMAL | WYETH | 2004-06-01 | — | — | US | disclosed |
| US-6649603-B2 | For therapy of metabolic disorders related to insulin resistance or hyperglycemia | WYETH | 2003-11-18 | — | — | US | disclosed |
| US-20030176412-A1 | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists | WYETH | 2003-09-18 | — | — | US | disclosed |
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2003-07-31 | — | — | US | disclosed |
| EP-1328512-A2 | CYCLYLAMINE SULFONAMIDES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | Wyeth (US) | 2003-07-23 | — | — | EP | disclosed |
| US-6583140-B2 | Useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia, atherosclerosis, gastrointestinal disorders | WYETH | 2003-06-24 | — | — | US | disclosed |
| EP-1301482-A1 | CYCLIC AMINE PHENYL BETA-3 ADRENERGIC RECEPTOR AGONISTS | Wyeth (US) | 2003-04-16 | — | — | EP | disclosed |
| US-6525202-B2 | E.g., substituted (4-amino-5-hydroxyphenyl)-oxy-)piperidinyl thiazolidin-2,4-dione; antidiabetic agents; atherosclerosis, gastrointestinal, metabolic disorders, glaucoma, neurogenetic inflammation, ocular hypertension and frequent urination | WYETH | 2003-02-25 | — | — | US | disclosed |
| US-20020169325-A1 | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists | WYETH | 2002-11-14 | — | — | US | disclosed |
| US-6444685-B1 | THERAPY FOR METABOLISM DISEASES; DIETETICS; ANTIDIABETIC AGENTS | WYETH | 2002-09-03 | — | — | US | disclosed |
| US-6410734-B1 | INSULIN RESISTANCE; HYPOGLYCEMIC AGENTS; ANTICHOLESTEROL AGENTS; GASTROINTESTINAL DISORDERS | WYETH | 2002-06-25 | — | — | US | disclosed |
| US-20020028797-A1 | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-07 | — | — | US | disclosed |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2002-03-07 | — | — | US | disclosed |
| US-20020022605-A1 | Cyclamine sulfonamides as beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-02-21 | — | — | US | disclosed |
| WO-2002006281-A1 | 2-SUBSTITUTED THIAZOLIDINONES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2002006221-A2 | CYCLYLAMINE SULFONAMIDES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2002006232-A1 | CYCLIC AMINE PHENYL BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2002006274-A1 | N-(4-SULFONYLARYL)CYCLYLAMINE-2-HYDROXYETHYLAMINES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | PTGS1 421/4885SLC6A2 144/4885KMT2A 3638/4885 |
| US-20020022605-A1 | Cyclamine sulfonamides as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | PTGS1 3320/4885SLC6A2 452/4885KMT2A 2355/4885 |
| US-20020169325-A1 | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | PTGS1 1898/4885SLC6A2 168/4885KMT2A 3512/4885 |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | PTGS1 421/4885SLC6A2 144/4885KMT2A 3638/4885 |
| US-20020028797-A1 | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | PTGS1 3649/4885SLC6A2 168/4885KMT2A 906/4885 |
| US-20030176412-A1 | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | PTGS1 1898/4885SLC6A2 168/4885KMT2A 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.